002581 Shandong Sinobioway Biomedicine
- 12.35
- -0.03-0.24%
Shandong Sinobioway Biomedicine News
Despite Currently Being Unprofitable, Shandong Sinobioway Biomedicine (SZSE:002581) Has Delivered a 88% Return to Shareholders Over 5 Years
Shandong Sinobioway Biomedicine (002581.SZ) has appointed Zhou Ting as the financial director.
Shandong Sinobioway Biomedicine (002581.SZ) announced that the company's board of directors recently received a report from the Chief Financial Officer, Mr. Liu Yangjun...
Shandong Sinobioway Biomedicine (002581.SZ) plans to launch a stock options incentive plan for 2024, with an exercise price of 12.35 yuan per share.
Shandong Sinobioway Biomedicine (002581.SZ) has announced the 2024 stock options incentive plan (draft), which grants...
We're Not Very Worried About Shandong Sinobioway Biomedicine's (SZSE:002581) Cash Burn Rate
Unnamed Pharmaceuticals: Report for the third quarter of 2024
Shandong Sinobioway Biomedicine (002581.SZ): The net income in the first three quarters was 14.6263 million yuan, a year-on-year decrease of 50.78%.
Glory Run on October 29丨Shandong Sinobioway Biomedicine (002581.SZ) announced its third quarter report for 2024, with the company achieving revenue of 0.315 billion yuan in the first three quarters, a 6.99% year-on-year decrease; net income attributable to shareholders of the listed company was 14.6263 million yuan, a 50.78% year-on-year decrease; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 16.5706 million yuan, a 49.02% year-on-year decrease; and basic earnings per share was 0.0222 yuan.
Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) 43% Share Price Surge Not Quite Adding Up
Unnamed Pharmaceuticals: 2024 Semi-Annual Report Summary
Unnamed Pharmaceuticals: Semi-Annual Report 2024
Shandong Sinobioway Biomedicine (002581.SZ) released its half-year performance, with a net loss of 29.6149 million yuan, narrowing by 44.91% year-on-year.
Shandong Sinobioway Biomedicine (002581.SZ) released its 2024 semi-annual report, with revenue of 0.21 billion yuan, a year-on-year increase...
Shandong Sinobioway Biomedicine (002581.SZ): Net loss of 296.149 million yuan in the first half of the year, with a narrowing loss compared to the same period last year.
Shandong Sinobioway Biomedicine (002581.SZ) announced its interim report for the first half of 2024, with a reported revenue of 0.211 billion yuan, a year-on-year increase of 0.77%; a net loss attributable to shareholders of the listed company of -29.6149 million yuan, with a narrower year-on-year loss; a non-recurring profit and loss deducted net profit attributable to shareholders of the listed company of -26.9934 million yuan; basic earnings per share of -0.0449 yuan.
The One-year Earnings Decline Has Likely Contributed ToShandong Sinobioway Biomedicine's (SZSE:002581) Shareholders Losses of 48% Over That Period
Shandong Sinobioway Biomedicine (002581.SZ) plans to transfer 26.838% stake in Yingkou Chemical for a listing price of 98.0468 million yuan.
On August 1st, Gelunhui reported that Shandong Sinobioway Biomedicine (002581.SZ) plans to sell 26.8380% equity of Yingkou Yingsheng Chemical Technology Co., Ltd. (hereinafter referred to as “Yingkou Chemical”), held by its wholly-owned subsidiary Shandong Wei Ming Tian Yuan Biotechnology Co., Ltd. (hereinafter referred to as "Wei Ming Tian Yuan"), through public listing on the Shandong Property Rights Trading Center, to further optimize resource allocation, improve asset quality, and increase operational efficiency. The first-time public listing transfer price will not be lower than the assessment value of the target assets by the asset appraisal institution. This equity transfer is planned because the participating company's equity is to be transferred.
Shandong Sinobioway Biomedicine: 2024 Interim Performance Forecast
Shandong Sinobioway Biomedicine (002581.SZ): expected pre-loss of 23 million yuan to 42 million yuan in the first half of the year.
On July 12th, Gelunhui reported that Shandong Sinobioway Biomedicine (002581.SZ) announced its performance forecast for the first half of 2024, with a net loss of 23-42 million yuan attributable to shareholders of listed companies, compared with a loss of 53.7573 million yuan in the same period last year; the net loss after deducting non-recurring gains and losses is 20.4-39.4 million yuan, compared with a loss of 48.1417 million yuan in the same period last year; the basic earnings per share were a loss of 0.0349 yuan/share to 0.0637 yuan/share. The reason for the company's loss during the reporting period was due to the decrease in the investment income of the company, and the company will further carry out a new round of global strategic development.
Some Confidence Is Lacking In Shandong Sinobioway Biomedicine Co., Ltd.'s (SZSE:002581) P/S
Unnamed Pharmaceutical (002581.SZ) withdraws from Qianhai Weiming M&A Fund
Unnamed Pharmaceutical (002581.SZ) issued an announcement, and the company held the 5th term of directors on May 30, 2024...
Unnamed Pharmaceutical (002581.SZ) received a dividend of 215 million yuan from the participating company Beijing Kexing
Unnamed Pharmaceutical (002581.SZ) announced that the company received a shareholding company, Beijing Kexing Biological Products Co., Ltd. (abbreviation...
Shareholders Have Faith in Loss-making Shandong Sinobioway Biomedicine (SZSE:002581) as Stock Climbs 10% in Past Week, Taking Five-year Gain to 83%
Unnamed Pharmaceutical (002581.SZ): Net loss of 27.704 million yuan in the first quarter
On April 30, Ge Longhui Pharmaceutical (002581.SZ) released its report for the first quarter of 2024, achieving operating income of 83.8048 million yuan, an increase of 10.85% over the previous year; net profit attributable to shareholders of listed companies - 27.704 million yuan, net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 28.33 million yuan, and basic earnings per share - 0.042 yuan.
No Data
